Pembrolizumab‐associated chronic rhinosinusitis: A new endotype and management considerations
Taylor Standiford, Neil N. Patel, Amritpal Singh, Grant E. Gochman, Tara Jamie Wu, Adil Daud, Andrew N. Goldberg
Abstract
KEY POINTS: Patients treated with pembrolizumab experience an increase in paranasal sinus inflammation Use of topical triamcinolone in carboxymethylcellulose is a treatment option for such patients.
Topics & Concepts
MedicinePembrolizumabChronic rhinosinusitisEndotypeDermatologySinusitisTriamcinolone acetonideIntensive care medicineInternal medicineSurgeryImmunotherapyAsthmaCancerSinusitis and nasal conditionsCancer Immunotherapy and BiomarkersDrug-Induced Adverse Reactions